Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy

Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy

A considerable amount of melanoma patients show primary resistance to PD-1 and CTLA-4 inhibitors. We have previously reported a beneficial role of intralesional Interleukin-2 (IL-2) in 9 melanoma patients developing new locoregional metastases under immunotherapy. We have now expanded this retrospec...

Full description

Bibliographic Details
Main Authors: David Rafei-Shamsabadi, Saskia Lehr, Max Behrens, Frank Meiss
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
metastatic melanoma
Interleukin-2
intralesional
combination therapy
PD-1 inhibitor
Online Access:https://www.mdpi.com/2072-6694/14/3/540

Internet

https://www.mdpi.com/2072-6694/14/3/540

Similar Items